Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paweł Łaguna has a total of 344 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Treatment Outcomes and Prognostic Factors in Children with Myeloid Leukemia Associated with Down Syndrome: A Nationwide Polish Retrospective Study

    by Katarzyna Pawińska-Wąsikowska, Małgorzata Czogała, Karolina Bukowska-Strakova, Teofila Książek, Agnieszka Pac, Magdalena Samborska, Jacek Wachowiak, Anna Tomoń, Radosław Chaber, Karolina Zielezińska, et al.

    Background: Significant progress has been achieved in the treatment of children with myeloid leukemia associated with Down syndrome (ML-DS). We aimed to evaluate treatment outcomes and prognostic factors in children with ML-DS treated in Poland. Methods: Thirty-six children with ML-DS treated at pediatric hematology and oncology centers in Poland according to the ML-DS 2006 protocol based on the AML-BFM backbone between 2015 and 2024 were retrospectively analyzed. Results: The estimated 5-year event-free survival (EFS) and overall survival (OS) were 84.3% (95%CI: 72.5–98.1%) and 87.9% (77.4–99.8%), respectively. Although children with a complex karyotype showed numerically lower survival estimates than those with isolated constitutional trisomy 21 or additional cytogenetic abnormalities (OS: 60% [95%CI: 29.3–100%] vs. 90% [73.2–100%] vs. 92.3% [78.9–100%], p = 0.24; EFS: 60% [95%CI: 29.3–100%) vs. 75% [49.6–100%] vs. 92.3% [78.9–100%], p = 0.26), p = 0.26), these differences were not statistically significant. MRD positivity (≥0.1%) after the second induction cycle was identified as an adverse prognostic factor in the univariable analysis (HR = 31.1, 95%CI: 2.74–353.2; p = 0.006). Conclusions: Persistent MRD positivity after the second induction cycle may identify children with ML-DS at increased risk of treatment failure. Larger multicenter studies are needed to validate the prognostic significance of MRD and recurrent molecular alterations to optimize risk-adapted treatment strategies.

  • Open Access

    Three-Dimensional Left Ventricle Strain Echocardiography in the Detection of Anthracycline Cardiotoxicity in Children with Acute Lymphoblastic Leukemia—Retrospective Case-Control Analysis and Relation to the Cardiotoxicity Risk Factors Assessment

    by Julia Haponiuk-Skwarlińska, Halszka Kamińska, Jakub S. Gąsior, Katarzyna Albrecht, Paweł Łaguna, Bożena Werner

    Background/Objectives: Acute lymphoblastic leukemia (ALL) treatment is effective but involves the use of cardiotoxic anthracyclines. Data on three-dimensional (3D) strain echocardiography utility in the monitoring of acute and early-onset cardiotoxicity in children with ALL are scarce. The aim was to assess the left ventricular function in 3D strain echocardiography in children with ALL treated with anthracyclines in reference to a healthy cohort and to assess risk factors of possible subclinical cardiotoxicity. Methods: For this study, medical records from between May 2023 and December 2024 were retrospectively analyzed, and the echocardiographic data were reassessed. The study group consisted of children diagnosed and treated for ALL for at least 6 months with the use of daunorubicin and doxorubicin (or only with daunorubicin) who underwent routine cardiological evaluation with 3D echocardiography in >6 months and 2. Statistically significant differences between study and control groups were observed in terms of LVEF 3D (53.9 ± 4.4% vs. 59.1 ± 5.8%, p < 0.001), GLS 3D (−21.8 ± 4.2% vs. −25.2 ± 3.6%, p < 0.001), GCS 3D (−22.3 ± 3.8% vs. −27.3 ± 4.7%, p < 0.001) and GRS 3D (37.1 ± 5.0% vs. 44.6 ± 5.7%, p < 0.001). None of the previously described cardiotoxicity risk factors—age at the diagnosis, sex, age at treatment initiation, body surface area (BSA) at treatment initiation, time since treatment initiation, ALL subtype, total anthracycline dose and doxorubicin treatment—were statistically significant in the GLS or GCS models. Conclusions: GLS 3D, GCS 3D and GRS 3D of the left ventricle may be sensitive indicators of myocardial dysfunction in children with ALL treated with anthracyclines. The relation of the previously described cardiotoxicity risk factors to the 3D strain values and myocardial dysfunction is inconclusive; further studies are warranted.

  • Open Access

    Combined SERS and chemometric analyses of blood plasma and bone marrow towards pediatric leukemia biomarkers detection

    by Patrycja Wiewiórowska, Magdalena Wołowiec, Marta Czaplicka, Sylwia Magdalena Berus, Mateusz Pielach, Paweł Łaguna, Aneta Aniela Kowalska, Agnieszka Kamińska

    The applicability of enhanced Raman spectroscopy (SERS) to differentiate acute lymphoblastic leukemia (ALL) in pediatric patients using clinically accessible biofluids remains unexplored. Therefore, this study addresses the need for a rapid, noninvasive method capable of distinguishing ALL from healthy conditions at the molecular level. Label-free SERS spectra obtained from bone marrow and blood plasma were analyzed using multivariate statistical methods supported by partial least squares regression, enabling discrimination between leukemia and healthy samples across three consecutive factors, which is 69%, 76% (X matrix), and 89%, 76% (Y matrix) for bone marrow and blood plasma, respectively. Moreover, the data calculated for blood plasma taken at diagnosis, consolidation, and control points explain 76% (X-matrix) and 66% (Y-matrix) of the total information. The corresponding weighted regression coefficients indicate that the variables at 653, 685, 724, 1002, and 1394 cm− 1 are marker bands in the presented analysis. Analyzing both types of samples (bone marrow and blood plasma) from one patient, we have found a strong relationship with the pediatric ALL patients’ condition. Graphical Abstract

  • Open Access

    The Outcomes of Myeloid Sarcoma in 64 Pediatric Patients and the Impact of Allogeneic Hematopoietic Stem Cell Transplantation on Treatment Results

    by Magdalena Samborska, Jolanta Skalska-Sadowska, Jacek Wachowiak, Małgorzata Czogała, Walentyna Balwierz, Szymon Skoczeń, Natalia Bartoszewicz, Jan Styczyński, Tomasz Ociepa, Tomasz Urasiński, et al.

    Background: Myeloid sarcoma (MS) is a malignant extramedullary tumor that occurs in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myeloid leukemia (CML). The standard first-line treatment for MS is intensive chemotherapy according to the AML protocol, regardless of bone marrow involvement. The role of allogeneic hematopoietic stem cell transplantation (alloHSCT) in the treatment of pediatric patients with MS requires further investigation. The aim of the study was to evaluate treatment outcomes for MS in pediatric patients with a focus on assessing the impact of allogeneic hematopoietic stem cell transplantation (alloHSCT) on treatment efficacy. Material and Methods: The study included 64 patients aged 0 to 19 years from 15 pediatric oncology centers in Poland who were diagnosed with MS between 1998 and 2024. An Excel database was created to collect data on clinical features and treatment methods and outcomes. Results: The probability of 5-year overall survival (pOS) for the entire cohort was 0.63 ± 0.07, while the 5-year event-free survival (pEFS) and 5-year relapse-free survival (pRFS) were 0.62 ± 0.07 and 0.72 ± 0.07, respectively. Treatment outcomes were compared between patients who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT) in first complete remission (ICR) (n1 = 17/64; 27%) and those who did not receive alloHSCT (n2 = 47/64; 73%). In the alloHSCT group (n1), the estimated survival probabilities were pOS = 0.49 ± 0.13, pEFS = 0.44 ± 0.14, and pRFS = 0.40 ± 0.14. In the non-alloHSCT group (n2), these values were pOS = 0.68 ± 0.08, pEFS = 0.68 ± 0.08, and pRFS = 0.84 ± 0.06. The difference in pRFS between groups n1 and n2 was statistically significant (p = 0.0049). Extramedullary relapses were more frequently observed in patients who had undergone allogeneic hematopoietic stem cell transplantation (alloHSCT) (p = 0.0001). Conclusions: Allogeneic hematopoietic stem cell transplantation (alloHSCT) does not improve the outcome of patients with MS. Further research is needed to identify effective strategies for sustaining remission in patients with MS after alloHSCT.


  • Open Access

    The Outcomes of Myeloid Sarcoma in 64 Pediatric Patients and the Impact of Allogeneic Hematopoietic Stem Cell Transplantation on Treatment Results

    by Magdalena Samborska, Jolanta Skalska-Sadowska, Jacek Wachowiak, Małgorzata Czogała, Walentyna Balwierz, Szymon Skoczen, Natalia Bartoszewicz, Jan Styczynski, Tomasz Ociepa, Tomasz Urasiński, et al.

    Myeloid sarcoma (MS) is a malignant extramedullary tumor that occurs in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myeloid leukemia (CML). The standard first-line treatment for MS is intensive chemotherapy according the AML protocol, regardless of bone marrow involvement. The role of allogeneic hematopoietic stem cell transplantation (alloHSCT) in the treatment of pediatric patients with MS requires further investigation. The aim of the study was to evaluate treatment outcomes for MS in pediatric patients with a focus on assessing the impact of allogeneic hematopoietic stem cell transplantation (alloHSCT) on treatment efficacy. The study included 64 patients aged 0 to 19 years from 15 pediatric oncology centers in Poland, who were diagnosed with MS between 1998 and 2024. The probability of 5-year overall survival (pOS) for the entire cohort was 0.63 ± 0.07, while the 5-year event-free survival (pEFS) and 5-year relapse-free survival (pRFS) were 0.62 ± 0.07 and 0.72 ± 0.07, respectively. Treatment outcomes were compared between patients who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT) in first complete remission (ICR) (n1 = 17/64; 27%) and those who did not receive alloHSCT (n2 = 47/64; 73%). In the alloHSCT group (n1), the estimated survival probabilities were pOS = 0.49 ± 0.13, pEFS = 0.44 ± 0.14, and pRFS = 0.40 ± 0.14. In the non-alloHSCT group (n2), these values were pOS = 0.68 ± 0.08, pEFS = 0.68 ± 0.08, and pRFS = 0.84 ± 0.06. The difference in pRFS between groups n1 and n2 was statistically significant (p = 0.0049). Extramedullary relapse was more frequently observed in patients who had undergone allogeneic hematopoietic stem cell transplantation (alloHSCT) (p = 0.0001). Further research is needed to identify effective strategies for sustaining remission in patients with MS after alloHSCT.

  • Open Access

    Impact of Acute Lymphoblastic Leukemia Treatment on Left Ventricular Function Assessed in 2D and 3D Speckle Tracing Echocardiography—Preliminary Results

    by Julia Haponiuk-Skwarlińska, Halszka Kamińska, Katarzyna Albrecht, Paweł Łaguna, Bożena Werner

    Background/Objectives: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy with promising survival. ALL treatment involves the use of cardiotoxic anthracyclines. The data for children on new methods of echocardiographic detection of early-onset anthracycline-related left ventricle dysfunction is lacking. Methods: Consecutive children with ALL were prospectively enrolled. The echocardiography was performed after ALL diagnosis and before initiation of anthracyclines (first assessment) and after induction and intensification therapy completion (second assessment). The left ventricle echocardiographic assessment involved conventional two-dimensional (2D) echocardiography, 2D speckle tracing, and three-dimensional (3D) echocardiography with offline analysis for 3D speckle tracing. Results: The preliminary group of 32 children presented with mean time between the first and second assessment of 7.3 ± 1.5 months (min.5.3–max.11.4). All children were treated by the same treatment protocol and received doxorubicin and daunorubicin. The mean cumulative equivalent anthracycline dose was 165.6 ± 54.0 mg/m2. Statistically significant differences between the first and the second echocardiography were observed in LV-GLS-2D −24.6 ± 3.3% vs. −21.0 ± 3.3%; p < 0.001, LVEF-3D 59.7 ± 7.3% vs. 55.1 ± 3.0%; p = 0.010, LV-GLS-3D −23.3 ± 5.3% vs. −20.4 ± 2.8%; p = 0.031 and LV-GCS-3D −26.3 ± 5.9% vs. −21.9 ± 3.2%; p = 0.017. The differences in LVEF-2D and LV-GRS-3D were not statistically significant. The decrease of >15% from the first assessment was observed in 9 (28%) in LV-GLS-2D, 8 (25%) in LV-GLS-3D, 11 (34%) in LV-GCS-3D and only in 4 (13%) patients in LV-GRS-3D. Conclusions: Two-dimensional and three-dimensional speckle tracing and 3D-LVEF may be sensitive indicators of subclinical left ventricular function impairment in children treated for ALL with anthracyclines. However, this is a preliminary analysis of the planned cohort; our results should be interpreted with caution.


  • Open Access

    Posterior Reversible Encephalopathy Syndrome in Children with Malignancies or After Hematopoietic Cell Transplantation: A Polish Nationwide Study

    by Tomasz Brzeski, Wanda Badowska, Katarzyna Mycko, Patrycja Tyszka, Martyna Korzeniewicz, Julia Kolodrubiec, Wojciech Mlynarski, Karolina Gawle-Krawczyk, Katarzyna Koch, Pawel Laguna, et al.

    Background/Objectives: The objective of this study was to analyze the clinical and laboratory features, management, outcomes, and complications of PRES in children with malignancies or following hematopoietic cell transplantation (HCT). Methods: This was a multicenter retrospective analysis of PRES episodes diagnosed between 2014 and 2022 in Polish pediatric hematology and oncology (PHO) centers and HCT units. The study included 438 patients treated for malignancy or post-HCT: 120 with PRES (study group) and 318 without PRES (control group). Results: PRES was diagnosed in children aged 1.7–16.5 years (median = 7.7 years). The most common underlying diagnosis was ALL (76.7%; n = 92). Symptoms of PRES included disturbances of consciousness (84.2%), seizures (80.0%), hypertension (74.2%), apathy (64.2%), abdominal pain (45.0%), visual disturbances (28.3%), and headaches (26.7%). Electrolyte abnormalities were observed in 75.0% of children, most commonly hyponatremia (49.2%) and hypokalemia (37.5%). Children with PRES were more likely to require admission to the intensive care unit (ICU) than controls (50.0% vs. 29.6%, p < 0.001). The most frequent long-term complications of PRES were hypertension (22.5%) and epilepsy (20.8%). Among PHO patients, those with PRES had significantly lower DFS (76.7% vs. 93.7%, p < 0.001) and OS (79.2% vs. 93.4%, p < 0.001). In the HCT group, PRES was also associated with lower DFS (40.0% vs. 83.3%, p = 0.012) and OS (40.0% vs. 77.8%, p = 0.047). Conclusions: PRES is a significant complication of oncological and transplant treatment in children. Its occurrence was associated with worse overall and disease-free survival. We proposed a predictive index for PRES, diagnostic criteria, and a revised name for this syndrome.


  • Open Access

    Evacuating Patients With Pediatric Cancer From Ukraine: Impact on Medical Care Capacity in Poland

    by Aleksandra Oszer, Khrystyna Kliuchkivska, Julia Kołodrubiec, Andriy Sopilnyak, Marta Salek, Marcin W. Włodarski, Małgorzata Dutkiewicz, Zuzanna Nowicka, Maryna Krawczuk-Rybak, Jan Styczyński, et al.

    PURPOSE: Soon after the Russian invasion of Ukraine in February 2022, an initiative was organized to evacuate Ukrainian children with cancer, most initially to Poland. This study assessed the impact of this rapid increase in clinical need on the Polish system of pediatric cancer care. METHODS: This multicenter longitudinal approach was performed among all 19 Polish Pediatric Oncology Centers (PPOCs). We compared PPOC capacity before the invasion with that during the first 11 weeks after the invasion, using three ratios: patients to physicians (PtP), patients to nurses (PtN), and patients to beds (PtB). In addition, we used national data from an ongoing leukemia clinical trial to assess differences between the two study periods in the time required to comply with protocol-indicated medical procedures requiring general anesthesia. RESULTS: During the study period, 237 Ukrainian refugee children with cancer were treated in PPOCs; 60% of them arrived during the first 21 days of the war. The relative increase in patients varied significantly among the PPOCs, ranging from 42% to 460%. The average PtP, PtN, and PtB ratios increased significantly by 85%, 131%, and 105%, respectively. The portion of patients experiencing a delay in obtaining medical procedures requiring general anesthesia increased from 15% before the war to 18.2% ( P = .043). CONCLUSION: Because of the large number of Ukrainian children with cancer were evacuated to Poland, capacity of PPOCs was reduced, affecting cancer care for all patients. Maintaining standards of pediatric oncology care in Poland would not be possible without further patient referral to medical facilities around the world by international humanitarian collaborative action.


  • Open Access

    Pleuropulmonary Blastoma in Children: A Nationwide Multicenter Study

    by Barbara Tejza, Marta Hetman, Jadwiga Węcławek-Tompol, Krzysztof Kałwak, Olga Rutynowska, Bożenna Dembowska-Bagińska, Agata Sobocińska-Mirska, Paweł Łaguna, Ewa Bień, Ninela Irga-Jaworska, et al.

    Background/Objectives: This study involved an analysis of clinical data, histological types, genetic predisposition, treatment and outcomes in PPB in children. Patients and methods: We conducted a retrospective review of children treated for PPB at Polish pediatric oncology centers between 2011 and 2024. Results: A total of fifteen children (seven boys, eight girls; median age of 39 months; range: 27–64 months) were included. Type II solid/cystic PPB and type III solid PPB were diagnosed in six and eight children, respectively (one not known). Overall, 93% of patients were diagnosed at up to 4 years of age. Metastatic disease at diagnosis was confirmed in three (20%) patients, localized in bones, bone marrow and lymph nodes. Diagnosis was confirmed via central pathology review in 11 patients (73%). DICER1 pathogenic variants were identified in eight patients. All children presented with respiratory symptoms. The tumor dimensions were >10 cm (n = 7), 5–10 cm (n = 5) and <5 cm (n = 2). No bilateral lung involvement was observed. Tumor biopsy was performed in six children (40%), with subsequent resection (R0) in five patients. Primary resection (R0) was achieved in three patients (20%) with type II (n = 1) or type III (n = 2). In the other six patients, non-radical resection was performed: R1 in four (27%) children (with a tumor rupture in one patient) and R2 (subtotal resection) in two children (13%). All patients received postoperative chemotherapy. Maintenance chemotherapy was given to two patients. No patient received radiotherapy as first-line treatment. Progressive disease occurred in two patients in the CNS and lungs. Relapsed disease appeared in three patients, all with CNS involvement. Conclusions: PPB is a rare, malignant tumor of early childhood with an uncertain prognosis. Despite multimodal treatment, patients remain at risk of progression or CNS relapse. Complete surgical resection remains a key prognostic factor.


  • Open Access

    Infections with Staphylococcus spp. in Children Undergoing Anticancer Therapy or Haematopoietic Cell Transplantation: A Nationwide Multicentre Study

    by Anna Jabłońska, Monika Richert-Przygońska, Kamila Jaremek, Krzysztof Czyżewski, Wanda Badowska, Walentyna Balwierz, Ewa Bień, Tomasz Brzeski, Radosław Chaber, Wojciech Czogała, et al.

    Background: Staphylococcus spp. represent the most prevalent Gram-positive organisms in children with malignancies or undergoing haematopoietic cell transplantation (HCT), contributing to significant morbidity and mortality. This study aimed to assess the epidemiology, risk factors, treatment strategies, and outcomes of staphylococcal infections (SIs) in paediatric haemato-oncology (PHO) and HCT patients in Poland over a 12-year period. Methods: A retrospective, multicentre study was conducted across 17 paediatric oncology centres in Poland. The clinical and microbiological data of patients under the age of 18, diagnosed with malignancies or post-HCT, were analysed for confirmed SI between 2012 and 2023. The variables assessed included demographics, underlying conditions, infection type and source, antimicrobial susceptibility, treatment, and 30-day infection-free survival. Results: Among 1725 patients with SI, 1433 were PHO and 292 were HCT patients. The cumulative incidence of SI was 12.7% in PHO and 14.3% in HCT patients (p = 0.008). The 30-day survival rate was significantly higher in PHO compared to HCT patients (98.4% vs. 93.2%, p < 0.001). Most deaths were caused by S. epidermidis, S. haemolyticus, and S. hominis, predominantly involving methicillin-resistant coagulase-negative Staphylococci (MRCNS). Multivariate Cox regression identified undergoing HCT (HR = 3.0, 95% CI: 1.6–5.6, p < 0.001) and treatment of infection > 10 days (HR = 2.0, 95% CI: 1.1–3.6, p = 0.019) as independent risk factors for mortality. Conclusions: Staphylococcal infections pose a significant challenge in paediatric oncology and transplant populations. Optimising prevention, diagnostics, and antimicrobial therapy is crucial for improving outcomes in these high-risk groups.